Nyxoah (NYXH)

Name: Nyxoah (NYXH) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Nyxoah (NYXH)

Stock Card

$1.62

$-0.14 (-7.95%)

As on 04-Sep-2026 16:26EDT

Market cap

$165 Mln

Revenue (TTM)

$23 Mln

P/E Ratio

P/B Ratio

1.6

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

Nyxoah (NYXH) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 1.59 High: 1.81

52 Week Range

Low: 1.26 High: 6.87

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-1.2 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-2
Debt to Equity

0.3
Book Value

$1
EPS

$-2.2
Face value

--
Shares outstanding

101,840,217

7 Years Aggregate

CFO

€-128.52 Mln

EBITDA

€-128.57 Mln

Net Profit

€-141.01 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Nyxoah (NYXH)	-64.8	11.0	-43.6	-72.4	-40.0	-44.6	--
BSE Sensex	-9.6	-2.7	2.9	-5.0	5.4	5.7	10.4
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 04-Sep-2026 | #As on 26-Oct-2023

Company	2025	2023	2022	2021
Nyxoah (NYXH)	-42.5	-7.0	-78.3	45.6
S&P Small-Cap 600	4.0	13.9	-17.4	25.3
BSE Sensex	9.1	18.7	4.4	22.0

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Nyxoah (NYXH)

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The... company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. Read more